Compare CINT & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CINT | EBS |
|---|---|---|
| Founded | 1995 | 1998 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 478.1M | 413.3M |
| IPO Year | 2021 | 2006 |
| Metric | CINT | EBS |
|---|---|---|
| Price | $3.35 | $7.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $7.35 | ★ $12.00 |
| AVG Volume (30 Days) | 129.0K | ★ 656.7K |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 125.83 |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $742,900,000.00 |
| Revenue This Year | $16.69 | $1.29 |
| Revenue Next Year | $11.28 | N/A |
| P/E Ratio | ★ $17.94 | $103.57 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.03 | $5.62 |
| 52 Week High | $6.06 | $14.06 |
| Indicator | CINT | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 48.90 | 34.23 |
| Support Level | $3.10 | N/A |
| Resistance Level | $3.59 | $8.59 |
| Average True Range (ATR) | 0.15 | 0.28 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 53.57 | 4.17 |
CI&T Inc operates as a partner in tech-integrated business solutions, helping organizations address complex challenges by integrating business approach, technology, and artificial intelligence into a single, coherent operating model. It is mainly engaged in the development of customizable software through the implementation of software solutions, including machine learning, artificial intelligence, data analytics, cloud migration and mobility technologies. The company provides technology services to various industry verticals, including Financial Services, Consumer Goods, Technology and Communications, Retail and Industrial Goods, Life Sciences, among others. The majority of the revenue is derived from providing technology services. Geographically, maximum revenue is derived from Brazil.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.